Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. Polycystic ovarian syndrome (PCOS) therapeutics market is rapidly growing due to factors such as growing prevalence, changing lifestyle pattern, early diagnosis and significant unmet needs.

The report titled “Polycystic ovarian syndrome (PCOS) therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2021-2029” offers strategic insights into the overall PCOS therapeutics market along with the market size and estimates for the duration 2019 to 2029. The research study covers in-depth analysis of market segments based on drug type and different geographical regions. Geographically, the global PCOS therapeutics market is studied for the following regional markets:

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe
• Asia-Pacific
• China
• Japan
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of LATAM
• Middle East and Africa
• GCC
• Rest of MEA

Market size and forecast for these regional and country level markets are presented in this study for the period 2018-2029. Market growth rates for the forecast period 2021-2029 are also included in this report, considering 2020 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global polycystic ovarian syndrome (PCOS) therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global polycystic ovarian syndrome (PCOS) therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global polycystic ovarian syndrome (PCOS) therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global polycystic ovarian syndrome (PCOS) therapeutics market, offering market size and estimates for the period from 2019 to 2029, keeping in mind the above-mentioned factors.

Based on drug type, the global polycystic ovarian syndrome (PCOS) therapeutics market is segmented as follows:

• Oral Contraceptive
• Ovulation Inducing Agents
• Facial Hair Growth Inhibitor
• Insulin Sensitizing Agent
• Other

Polycystic ovary syndrome (PCOS) is a hormonal disorder affecting approximately 10 percent of women of reproductive age. Women with PCOS may have infrequent or menstrual periods or excess male hormone levels. There is no cure for PCOS but treatment focuses on managing symptoms, such as infertility, hirsutism, acne or obesity. Change in lifestyle, increase in prevalence of PCOS and rising treatment awareness are prime factors that drive the growth of PCOS therapeutics market globally. For the purpose of the study PCOS therapeutics market is segmented on the basis of drug type such as oral contraceptive, ovulation inducing agents, facial hair growth inhibitor, insulin sensitizing agent and other therapeutics. Currently, oral contraceptive is the major revenue contributor because it is preferred as first line treatment option. Oral contraceptives are effective to regulate PCOS symptoms such as reduction of extra hair growth, lower risks for endometrial cancer, ovarian cancer, and ovarian cysts, cleansing the skin and to regulate the periods.

For the purpose of this study, the global polycystic ovarian syndrome (PCOS) therapeutics market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

According to national institutes of health (NIH), PCOS affects 8 to 20 percent of reproductive age women worldwide. In the base year 2020, North America dominated the polycystic ovarian syndrome (PCOS) therapeutics market. United States was largest revenue contributor due to the higher number of targeted population, higher cost of therapeutics, lifestyle pattern and higher treatment awareness among the general population. According to national institutes of health (NIH), PCOS affects more than 5 percent of women in the United States. On the other hand, rapid evolution of healthcare infrastructure, increasing number of target population, growing treatment awareness among the general population and increasing penetration of major market players will lead to Asia Pacific witnessing the fastest growth rate.


This product will be delivered within 2 business days.